Physician profile
David Bruce Simon
NPI 1811983125
$58,884.45
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $59K · 2020: $19.05 · 2023: $3.08.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $3.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $3.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $58,500.00 | 2019 | |
| Akebia Therapeutics INC | $87.14 | 2019 | |
| Amgen INC. | $65.90 | 2019 | |
| Baxter Healthcare | $36.96 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $36.83 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $30.28 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $24.41 | 2019 | |
| Novartis Pharmaceuticals Corporation | $22.23 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $22.17 | 2019 | |
| Mallinckrodt Enterprises LLC | $20.04 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $19.84 | 2019 | |
| Shire North American Group INC | $15.57 | 2019 | |
| Travere Therapeutics, INC. | $3.08 | 2023 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Simon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.